Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 28 | 2023 | 2118 | 1.350 |
Why?
|
| Neurons | 16 | 2014 | 342 | 1.260 |
Why?
|
| Cognition Disorders | 16 | 2010 | 1003 | 1.210 |
Why?
|
| Hippocampus | 7 | 2018 | 278 | 0.850 |
Why?
|
| Nerve Growth Factor | 4 | 2012 | 37 | 0.720 |
Why?
|
| Amyloid beta-Peptides | 6 | 2018 | 327 | 0.650 |
Why?
|
| Choline O-Acetyltransferase | 8 | 2005 | 21 | 0.640 |
Why?
|
| Immunohistochemistry | 17 | 2009 | 362 | 0.630 |
Why?
|
| Nerve Tissue Proteins | 6 | 2004 | 155 | 0.440 |
Why?
|
| Peptide Fragments | 2 | 2014 | 77 | 0.430 |
Why?
|
| Basal Nucleus of Meynert | 3 | 2002 | 10 | 0.420 |
Why?
|
| Protein Precursors | 1 | 2012 | 21 | 0.410 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 37 | 0.400 |
Why?
|
| RNA, Messenger | 3 | 2004 | 308 | 0.390 |
Why?
|
| Entorhinal Cortex | 4 | 2007 | 38 | 0.370 |
Why?
|
| Cognitive Dysfunction | 4 | 2022 | 1065 | 0.370 |
Why?
|
| Aged, 80 and over | 24 | 2015 | 4857 | 0.370 |
Why?
|
| Central Nervous System | 2 | 2003 | 59 | 0.360 |
Why?
|
| Animal Experimentation | 1 | 2010 | 3 | 0.360 |
Why?
|
| Frontal Lobe | 6 | 2022 | 81 | 0.360 |
Why?
|
| Dopamine | 6 | 2007 | 87 | 0.360 |
Why?
|
| F2-Isoprostanes | 1 | 2010 | 7 | 0.340 |
Why?
|
| Substantia Nigra | 5 | 2006 | 125 | 0.330 |
Why?
|
| Aged | 29 | 2015 | 9277 | 0.320 |
Why?
|
| Animals | 16 | 2018 | 3780 | 0.320 |
Why?
|
| Female | 30 | 2018 | 15725 | 0.310 |
Why?
|
| Corpus Striatum | 5 | 2010 | 65 | 0.290 |
Why?
|
| Male | 32 | 2018 | 15289 | 0.290 |
Why?
|
| Prosencephalon | 3 | 2005 | 8 | 0.290 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 1996 | 48 | 0.290 |
Why?
|
| Down-Regulation | 3 | 2002 | 102 | 0.280 |
Why?
|
| Humans | 40 | 2023 | 28431 | 0.270 |
Why?
|
| Peptides | 3 | 2018 | 103 | 0.270 |
Why?
|
| Macaca mulatta | 4 | 2010 | 61 | 0.270 |
Why?
|
| Cerebral Cortex | 4 | 2008 | 161 | 0.260 |
Why?
|
| Nerve Degeneration | 2 | 2009 | 49 | 0.250 |
Why?
|
| Membrane Transport Proteins | 2 | 2003 | 57 | 0.250 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 10 | 0.240 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2004 | 6 | 0.240 |
Why?
|
| Neuropsychological Tests | 12 | 2009 | 1226 | 0.230 |
Why?
|
| Receptor, trkA | 2 | 2001 | 9 | 0.230 |
Why?
|
| Cell Proliferation | 1 | 2004 | 178 | 0.220 |
Why?
|
| Nerve Growth Factors | 3 | 1999 | 37 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 2 | 2009 | 124 | 0.210 |
Why?
|
| Receptor, Nerve Growth Factor | 2 | 2002 | 9 | 0.210 |
Why?
|
| Insulins | 1 | 2022 | 4 | 0.210 |
Why?
|
| Tyrosine 3-Monooxygenase | 6 | 2010 | 53 | 0.200 |
Why?
|
| Acetylcholine | 1 | 2002 | 7 | 0.200 |
Why?
|
| Brain Mapping | 3 | 2022 | 150 | 0.190 |
Why?
|
| Parkinson Disease | 6 | 2010 | 859 | 0.190 |
Why?
|
| Aging | 7 | 2009 | 1550 | 0.190 |
Why?
|
| Axonal Transport | 2 | 1999 | 7 | 0.190 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2001 | 23 | 0.180 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 225 | 0.180 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 619 | 0.180 |
Why?
|
| tau Proteins | 5 | 2010 | 235 | 0.170 |
Why?
|
| Cholinergic Fibers | 3 | 2005 | 9 | 0.170 |
Why?
|
| Brain | 4 | 2022 | 1663 | 0.170 |
Why?
|
| Cell Count | 4 | 2006 | 79 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 21 | 0.150 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 33 | 0.150 |
Why?
|
| Genetic Therapy | 2 | 2010 | 85 | 0.140 |
Why?
|
| Limbic System | 1 | 1996 | 8 | 0.140 |
Why?
|
| Neuronal Plasticity | 3 | 2014 | 47 | 0.130 |
Why?
|
| Neostriatum | 1 | 1996 | 14 | 0.130 |
Why?
|
| Mice | 4 | 2018 | 1461 | 0.130 |
Why?
|
| Substantia Innominata | 2 | 2009 | 5 | 0.130 |
Why?
|
| Genotype | 3 | 2002 | 359 | 0.120 |
Why?
|
| Nootropic Agents | 1 | 2015 | 14 | 0.120 |
Why?
|
| Dendrites | 1 | 2014 | 10 | 0.120 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2014 | 8 | 0.120 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 4 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 1143 | 0.120 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 14 | 0.110 |
Why?
|
| Pyramidal Cells | 1 | 2014 | 34 | 0.110 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 128 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2015 | 162 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2006 | 172 | 0.110 |
Why?
|
| Stem Cells | 2 | 2004 | 41 | 0.110 |
Why?
|
| Rats | 4 | 2002 | 678 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 274 | 0.100 |
Why?
|
| Disease Progression | 5 | 2022 | 717 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1999 | 341 | 0.100 |
Why?
|
| Apoptosis | 1 | 2012 | 205 | 0.090 |
Why?
|
| Ubiquitin | 3 | 2009 | 31 | 0.090 |
Why?
|
| Macaca fascicularis | 2 | 2004 | 25 | 0.090 |
Why?
|
| Presenilin-1 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Gels | 1 | 2010 | 13 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 23 | 0.090 |
Why?
|
| Nitriles | 1 | 2010 | 14 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2010 | 17 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 38 | 0.090 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2002 | 9 | 0.090 |
Why?
|
| MPTP Poisoning | 1 | 2010 | 15 | 0.090 |
Why?
|
| Triazoles | 1 | 2010 | 29 | 0.090 |
Why?
|
| Neurturin | 1 | 2010 | 23 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2010 | 111 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 65 | 0.090 |
Why?
|
| Body Weight | 1 | 2010 | 144 | 0.090 |
Why?
|
| Amnesia | 1 | 2009 | 25 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2003 | 97 | 0.080 |
Why?
|
| Presynaptic Terminals | 2 | 2023 | 11 | 0.080 |
Why?
|
| Environment | 1 | 2009 | 47 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2009 | 52 | 0.080 |
Why?
|
| Neuropil Threads | 3 | 2007 | 7 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 737 | 0.070 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Cognition | 2 | 2014 | 1353 | 0.070 |
Why?
|
| Autopsy | 3 | 2009 | 343 | 0.070 |
Why?
|
| Middle Aged | 8 | 2015 | 9268 | 0.070 |
Why?
|
| Caspase 6 | 1 | 2007 | 8 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2007 | 118 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2007 | 44 | 0.070 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2006 | 28 | 0.060 |
Why?
|
| Infusions, Parenteral | 2 | 1996 | 9 | 0.060 |
Why?
|
| Plaque, Amyloid | 2 | 2007 | 146 | 0.060 |
Why?
|
| Visual Cortex | 1 | 2005 | 5 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 213 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 19 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2004 | 135 | 0.060 |
Why?
|
| Estradiol | 1 | 2004 | 39 | 0.060 |
Why?
|
| Ovariectomy | 2 | 2004 | 26 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 23 | 0.060 |
Why?
|
| Neurofibrillary Tangles | 4 | 2007 | 193 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Proteins | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 2 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2023 | 5 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2009 | 269 | 0.050 |
Why?
|
| Quinolinic Acid | 1 | 2002 | 11 | 0.050 |
Why?
|
| Propionates | 1 | 2002 | 12 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2002 | 16 | 0.050 |
Why?
|
| Parahippocampal Gyrus | 1 | 2002 | 7 | 0.050 |
Why?
|
| Parietal Lobe | 1 | 2002 | 17 | 0.050 |
Why?
|
| Causality | 1 | 2002 | 56 | 0.050 |
Why?
|
| Neuroglia | 1 | 2002 | 49 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2002 | 84 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 281 | 0.050 |
Why?
|
| Neurobehavioral Manifestations | 1 | 2000 | 2 | 0.050 |
Why?
|
| Atrophy | 1 | 2001 | 93 | 0.040 |
Why?
|
| Mesencephalon | 2 | 2007 | 26 | 0.040 |
Why?
|
| Injections, Intraventricular | 2 | 1999 | 8 | 0.040 |
Why?
|
| Organ Specificity | 1 | 1999 | 42 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 1999 | 15 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 1999 | 10 | 0.040 |
Why?
|
| Catholicism | 1 | 1999 | 20 | 0.040 |
Why?
|
| Synaptophysin | 2 | 2009 | 9 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 1999 | 60 | 0.040 |
Why?
|
| Age Factors | 1 | 2002 | 781 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 1999 | 6 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 1999 | 106 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 1999 | 55 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 1999 | 252 | 0.040 |
Why?
|
| Occipital Lobe | 1 | 1996 | 6 | 0.030 |
Why?
|
| Biological Transport | 1 | 1996 | 40 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 49 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 199 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 284 | 0.030 |
Why?
|
| Injections | 1 | 1996 | 44 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 539 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 447 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2009 | 169 | 0.030 |
Why?
|
| Dementia | 1 | 2000 | 575 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2015 | 27 | 0.030 |
Why?
|
| Turkeys | 1 | 1994 | 1 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 2014 | 7 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 27 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 2 | 2006 | 12 | 0.030 |
Why?
|
| Antibodies | 1 | 1994 | 49 | 0.030 |
Why?
|
| Axons | 1 | 2014 | 28 | 0.030 |
Why?
|
| Synapses | 1 | 2014 | 36 | 0.030 |
Why?
|
| Models, Animal | 1 | 2014 | 115 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 35 | 0.030 |
Why?
|
| alpha-Synuclein | 2 | 2006 | 133 | 0.030 |
Why?
|
| Tissue Extracts | 1 | 1993 | 9 | 0.030 |
Why?
|
| United States | 1 | 1999 | 2200 | 0.030 |
Why?
|
| Adult | 3 | 2015 | 8104 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 988 | 0.020 |
Why?
|
| Phenotype | 2 | 2002 | 313 | 0.020 |
Why?
|
| Dependovirus | 1 | 2010 | 40 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 62 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 107 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 6 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2009 | 11 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 67 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2009 | 29 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2005 | 1384 | 0.020 |
Why?
|
| Oleanolic Acid | 1 | 2009 | 6 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2009 | 42 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 102 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 31 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 326 | 0.020 |
Why?
|
| Adolescent | 2 | 2007 | 2307 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2008 | 5 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Biomarkers | 2 | 2002 | 596 | 0.020 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2007 | 20 | 0.020 |
Why?
|
| Amyloid | 1 | 2008 | 56 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 75 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2009 | 264 | 0.020 |
Why?
|
| Isoprostanes | 1 | 2007 | 2 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 13 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 40 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 120 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 435 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 33 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 30 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 194 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2005 | 59 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 37 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 329 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 89 | 0.010 |
Why?
|
| Synucleins | 1 | 2004 | 7 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 57 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 148 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 146 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2004 | 114 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 25 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 58 | 0.010 |
Why?
|
| Child | 1 | 2007 | 1420 | 0.010 |
Why?
|
| Nitro Compounds | 1 | 2002 | 9 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 24 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 106 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 35 | 0.010 |
Why?
|
| Silver Staining | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cell Size | 1 | 2001 | 6 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 351 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 251 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 2000 | 6 | 0.010 |
Why?
|
| Lewy Bodies | 1 | 2002 | 194 | 0.010 |
Why?
|
| Vesicular Acetylcholine Transport Proteins | 1 | 1999 | 2 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 32 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 1999 | 26 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2001 | 289 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 1491 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 1809 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 1993 | 11 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 83 | 0.010 |
Why?
|
| Putamen | 1 | 1993 | 20 | 0.010 |
Why?
|
| Cerebellum | 1 | 1993 | 46 | 0.010 |
Why?
|